A new study reveals how C210, a curcumin derivative, selectively reactivates Epstein–Barr virus to kill cancer cells without infectious risks, paving the way for safer, targeted cancer therapies.
Researchers at the Wistar Institute and their collaborators say they have discovered a potential target for gastric cancers associated with Epstein-Barr Virus. The study “Decitabine disrupts EBV ...
Phase I clinical and pharmacokinetic (PK) trial of the kinesin spindle protein (KSP) inhibitor MK-0731 in cancer patients No significant financial relationships to disclose. This is an ASCO Meeting ...
A team of UC Davis researchers has identified a protein in the cancer cell’s nucleus as a critical agent keeping Kaposi's sarcoma-associated herpesvirus (KSHV) dormant and undetected by the body’s ...
In a recent study published in the journal PLoS Pathogens, researchers analyze prophages of the LF82 strain of adherent-invasive Escherichia coli (AIEC) to better understand their behavior in vitro ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results